HRT and GLP-1 Weight Loss: Estrogen, Progesterone, Menopause Timing, and Combined Use Evidence

Millions of perimenopausal and postmenopausal women are now on hormone replacement therapy (HRT) and asking whether it is safe to start a GLP-1, or whether HRT will blunt their weight loss. The short answer backed by verified primary sources: the drug interaction risk between injectable HRT (patches, gels, vaginal rings) and GLP-1 medications is minimal to none. The interaction risk between oral hormonal medications and tirzepatide-class drugs (Zepbound, Mounjaro) is real and FDA-labeled. HRT itself does not cause clinically meaningful weight gain per the Cochrane pooled analysis of 28 RCTs (Norman 2000). And post-menopausal women respond to GLP-1 weight-loss therapy at rates comparable to pre-menopausal women — the SURMOUNT post-hoc analysis (Tchang 2025, PMID 40074721) documented 23% body weight reduction with tirzepatide in postmenopausal women vs 2% placebo. Here is the complete evidence picture, organized around the five questions this population actually asks.

TL;DR — 5 things to know

1. Tirzepatide (Zepbound/Mounjaro) is the only GLP-1 with an FDA-label warning for oral hormonal medications. A single 5 mg tirzepatide dose reduced peak oral contraceptive concentrations by 55–66% and overall exposure by 20–23%. The same mechanism applies to oral estrogen and oral progesterone taken at the same time. Semaglutide (Wegovy, Ozempic) showed no clinically relevant effect in the same type of pharmacokinetic study.
2. Transdermal and vaginal HRT bypasses the gastric-emptying interaction entirely. Patches, gels, rings, and vaginal inserts absorb directly through skin or mucosa — GLP-1-mediated gastric emptying delay has no pharmacological pathway to affect them.
3. HRT does not meaningfully cause weight gain. The Norman 2000 Cochrane review of 28 RCTs (n = 28,559) found a mean weight difference of 0.03 kg between unopposed estrogen and placebo — essentially zero. Combined estrogen + progestogen also showed no significant weight increase.
4. Post-menopausal women lose weight on GLP-1s at rates similar to pre-menopausal women. SURMOUNT-1 post-hoc analysis (PMID 40074721) showed 23% body weight reduction with tirzepatide in both peri- and post-menopausal participants vs 3% placebo, with waist circumference reductions of ~20 cm.
5. The right sequencing question is about symptoms and bone density, not about weight-loss competition. HRT treats vasomotor symptoms and protects bone. GLP-1 treats obesity. The 2022 NAMS position statement (PMID 35797481) supports HRT for women under 60 or within 10 years of menopause onset with appropriate risk-benefit assessment. These goals are complementary, not competing.

Are there drug-drug interactions between HRT and GLP-1s?

The most important framing first: HRT encompasses multiple formulations with entirely different absorption routes. Oral HRT (estrogen tablets, progesterone capsules like Prometrium) is absorbed through the GI tract and is therefore theoretically subject to any GLP-1-induced gastric emptying delay. Transdermal HRT (Climara patch, Divigel gel, Elestrin gel, EstroGel) absorbs directly through skin. Vaginal HRT (Vagifem inserts, Estrace cream, Premarin cream, Estring, Femring) is absorbed through vaginal mucosa. Route of administration is everything in this interaction picture.

Wegovy (semaglutide 2.4 mg) and Ozempic (semaglutide 1 mg) — Section 7 Drug Interactions

The Wegovy prescribing information (DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b, Section 7.2) states:

“WEGOVY causes a delay of gastric emptying and thereby has the potential to impact the absorption of concomitantly administered oral medications.”

However, the Ozempic prescribing information (DailyMed SetID adec4fd2-6858-4c99-91d4-531f5f2a2d79, Section 7) is more specific about the clinical significance:

“In clinical pharmacology trials, semaglutide did not affect the absorption of orally administered medications to any clinically relevant degree.”

The Ozempic label includes a Figure showing pharmacokinetic data for co-administered oral medications — including oral contraceptives containing ethinyl estradiol and levonorgestrel. Relative exposure (AUC and Cmax) showed no clinically significant changes. The label advises “caution should be exercised when oral medications are concomitantly administered with OZEMPIC” as a general principle, but the underlying data showed no meaningful interaction with oral hormonal medications.

Bottom line for semaglutide (Wegovy/Ozempic): the gastric-emptying mechanism exists on paper, but clinical pharmacology data showed no relevant absorption change for oral contraceptives. The same conclusion applies to oral systemic HRT products — no specific interaction study has been published, but the oral contraceptive surrogate data is reassuring. Patients on oral HRT + Wegovy/Ozempic should discuss timing of their oral medications with their prescriber; taking oral HRT at a consistent time (e.g., 30 minutes before the GLP-1 injection day meal) is a practical precaution.

Saxenda (liraglutide 3 mg) — Section 7 Drug Interactions

The Saxenda prescribing information (DailyMed SetID 3946d389-0926-4f77-a708-0acb8153b143) specifically tested an oral contraceptive containing ethinylestradiol and levonorgestrel administered 7 hours after liraglutide. The results:

Ethinylestradiol peak concentration (Cmax) decreased by 12%; levonorgestrel Cmax decreased by 13%. Overall exposure (AUC) to ethinylestradiol showed no change; levonorgestrel AUC increased by 18%. Peak absorption timing was delayed by 1.5 hours for both compounds.

These Cmax reductions (12–13%) with liraglutide were smaller than those seen with tirzepatide (55–66%). The Saxenda label does not include a specific warning for oral hormonal contraceptives or HRT beyond the general caution to “monitor for potential consequences of delayed absorption of oral medications concomitantly administered with SAXENDA.”

Zepbound (tirzepatide) and Mounjaro (tirzepatide) — Section 7: The labeled oral hormonal contraceptive interaction

Tirzepatide is in a different category from semaglutide and liraglutide. The Zepbound prescribing information (DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b) and the Mounjaro prescribing information (DailyMed SetID d2d7da5d-ad07-4228-955f-cf7e355c8cc0) both contain explicit language on oral hormonal contraceptives:

“Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation.”

“Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO.”

The clinical pharmacology data supporting this warning: a single 5 mg tirzepatide dose co-administered with an oral contraceptive containing ethinyl estradiol and norgestimate produced:

• Peak concentration (Cmax) reductions of 55–66%
• Overall exposure (AUC) reductions of 20–23%
• Absorption timing delayed 2.5–4.5 hours

Both labels confirm that hormonal contraceptives administered through non-oral routes “should not be affected.” This exempts transdermal patches, vaginal rings, hormonal IUDs, implants, and injections from the interaction warning.

What this means for oral HRT + tirzepatide: The label warning is specifically written for oral contraceptives used to prevent pregnancy (because reduced efficacy has clinical consequences). Oral HRT products — estradiol tablets, Premarin tablets, Prometrium capsules — are chemically similar oral hormonal medications and would be subject to the same gastric-emptying-driven absorption reduction. The clinical consequence for HRT is different from the consequence for contraception (a 20% AUC reduction in Premarin is less immediately critical than a 20% AUC reduction in a birth control pill), but it may affect symptom control. Women on oral HRT + tirzepatide should discuss switching to a patch, gel, or other transdermal formulation with their prescriber. Transdermal formulations are also generally preferred in postmenopausal women due to their lower first-pass hepatic metabolism profile.

Why menopause causes weight gain in the first place

The weight changes that accompany menopause are not simply “getting older.” They reflect specific hormonal mechanisms that are distinct from general aging and that are recoverable in part with targeted interventions.

The longitudinal evidence: Lovejoy 2008 (PMID 18332882)

Lovejoy and colleagues followed 156 women (103 Caucasian, 53 African American) for 4 years from a premenopausal baseline through the menopausal transition. Their findings, confirmed by dual-energy X-ray absorptiometry and computed tomography of visceral and subcutaneous abdominal fat, were:

• Visceral adipose tissue (VAT) increased significantly at menopause onset, independent of total body weight changes
• Total body fat increased across the transition
• Resting energy expenditure decreased at menopause (measured by whole-room calorimeter in a subset of 34 women)
• Fat oxidation decreased with declining estrogen

The critical insight from Lovejoy: visceral adipose tissue increased independently of total body weight. Many perimenopausal women report “I haven't gained weight but my belly is bigger” — this is real, documented, and mechanistically grounded.

The molecular mechanism: Kuryłowicz 2023 (PMID 36979669)

Kuryłowicz's 2023 review in Biomedicines identifies the central driver: estrogen receptor alpha (ERα) predominates in adipocyte regulation. When estrogen declines at menopause:

• ERα-mediated regulation of adipocyte differentiation and lipid metabolism is lost, favoring visceral fat accumulation
• Leptin synthesis is altered (leptin is partly estrogen-regulated)
• Peripheral insulin sensitivity decreases, creating a prediabetic metabolic environment in some women
• Fat distribution shifts from gynoid (hip/thigh) to android (visceral/abdominal) patterns

Energy metabolism dysregulation: Ko & Jung 2021 (PMID 34960109)

Ko and Jung's 2021 review in Nutrients describes the downstream lipid metabolic consequences: because genes involved in β-oxidation are downregulated by estradiol loss, excess free fatty acids produced by visceral fat lipolysis cannot be efficiently burned as energy. Increased adipogenesis results from upregulated gene expression related to fat accumulation. The net effect is a shift away from fat catabolism and toward fat synthesis — a double metabolic hit that compounds the visceral redistribution documented by Lovejoy.

This mechanistic picture explains why GLP-1s are particularly relevant in this population: they address both the caloric intake side (appetite suppression, slowed gastric emptying) and the adipose biology side (weight-loss-driven insulin sensitivity improvement, visceral fat reduction), while HRT addresses the upstream hormonal deficit that initiated the metabolic shift.

Does HRT itself cause weight gain or loss?

This question carries decades of patient anxiety driven by widely circulated but poorly sourced claims that HRT “makes you fat.” The primary-source evidence does not support this claim.

The Cochrane evidence: 28 RCTs, 28,559 women

The Norman 2000 Cochrane systematic review pooled 28 randomized trials of estrogen-only and combined estrogen + progestogen HRT and reported:

• Unopposed estrogen vs no HRT: mean weight difference 0.03 kg (95% CI −0.61 to 0.67) — not distinguishable from zero
• Combined estrogen + progestogen vs no HRT: no significant weight increase in the pooled analysis
• Conclusion: “Hormone replacement therapy has no effect on body weight and cannot prevent weight gain at menopause.” (Cochrane Plain Language Summary)

The clinical significance: HRT does not make you gain weight, but it also does not make you lose weight. The age-related weight gain that accompanies menopause is driven by the mechanisms described above (reduced energy expenditure, visceral redistribution), not by the HRT itself. The Cochrane conclusion is that HRT neither prevents nor causes the weight gain of the menopausal transition.

Younglove 2026 clinical review (PMID 41883510)

A 2026 clinical review in Obesity Pillars (Younglove, Heartland Weight Loss) synthesized the current evidence specifically at the intersection of menopause hormone therapy (MHT) and weight management for perimenopausal and postmenopausal women with obesity or overweight. The conclusions directly relevant to GLP-1 users:

“While these changes [menopausal body composition shifts] are primarily driven by estrogen deficiency and evidence from randomized trials and meta-analyses demonstrates that MHT may attenuate central fat accumulation and preserve favorable body composition, it is not indicated as a primary weight loss intervention.”

“Although recent observational data suggest potential synergistic effects when MHT is combined with obesity medications (OMs), these findings are limited by small sample sizes, retrospective design, and potential confounding, requiring validation through rigorous clinical trials.”

The Younglove review also specifically addresses the PREMARIN adverse reaction profile. The Premarin prescribing information (DailyMed SetID 258e1602-a3cf-4ccc-ca80-73dbbfb812ff, Section 6.1) lists “weight gain” as a treatment-related adverse reaction in 3% of patients on 0.625 mg vs 4% on placebo. The label also notes “increase or decrease in weight” in postmarketing experience — demonstrating that weight changes occur in both directions and at rates comparable to placebo. No net meaningful weight gain attributable to Premarin is established in the labeling data.

HRT and body composition: the nuanced picture

The emerging picture from body composition research (not total body weight) is more nuanced than the Cochrane weight data alone suggests. Kuryłowicz 2023 (PMID 36979669) documents that estrogen replacement can partially restore favorable fat distribution — attenuating the gynoid-to-android shift that accompanies menopause. The mechanism: ERα re-activation in adipocytes reverses some of the pro-visceral-fat transcription changes. Younglove 2026 corroborates: “MHT may attenuate central fat accumulation and preserve favorable body composition.” The practical clinical summary for women asking about HRT + GLP-1: HRT is not a weight-loss drug, but it may modestly improve fat distribution; GLP-1 produces the primary weight-reduction and metabolic improvement; together they address different parts of the menopausal metabolic problem.

Post-menopausal subgroup data from STEP and SURMOUNT

The fundamental question for any menopausal woman considering a GLP-1 is: does menopause status blunt the weight-loss response? The post-hoc data from the landmark obesity trials answers this question directly.

SURMOUNT post-hoc analysis by reproductive stage: Tchang 2025 (PMID 40074721)

Tchang and colleagues performed a post-hoc analysis of women from SURMOUNT-1, -3, and -4 who were randomized to tirzepatide (15 mg or maximum tolerated dose) or placebo, stratified by reproductive stage (pre-, peri-, and post-menopausal). This is the most directly relevant published dataset for answering the menopausal response question.

Published in Obesity (Silver Spring), May 2025, the key SURMOUNT-1 findings:

• Premenopausal: tirzepatide −26% vs placebo −2% body weight (p < 0.001)
• Perimenopausal: tirzepatide −23% vs placebo −3% (p < 0.001)
• Postmenopausal: tirzepatide −23% vs placebo −3% (p < 0.001)
• Waist circumference, premenopausal: −22 cm vs −4 cm
• Waist circumference, perimenopausal: −20 cm vs −5 cm
• Waist circumference, postmenopausal: −20 cm vs −4 cm
• Threshold achievement: 97–98% of tirzepatide participants across all reproductive stage subgroups achieved ≥5% body weight reduction vs 29–33% with placebo

The authors' conclusion: “In this post hoc analysis, tirzepatide treatment was associated with significant body weight, waist circumference, and WHtR reductions versus placebo in women living with obesity or overweight and without type 2 diabetes, irrespective of reproductive stage.”

Importantly, the visceral fat metric (waist circumference) was reduced by approximately 20 cm in both peri- and post-menopausal women — directly addressing the pattern of menopausal visceral redistribution documented by Lovejoy 2008. This is not a trivial number: 20 cm waist circumference reduction in a population specifically characterized by visceral fat accumulation is a meaningful body composition benefit beyond the headline weight loss.

STEP-1 (semaglutide 2.4 mg): women's subgroup

STEP-1 (Wilding 2021, PMID 33567185) enrolled 2,652 adults (74.1% women) with a mean age of 46.3 years and a mean baseline BMI of 37.9 kg/m². The trial did not publish a specific postmenopausal subgroup analysis in the primary paper, but the overall women's data from the STEP program showed greater percentage weight loss in women than in men (approximately −14% vs −8% in the published sex-stratified analyses), suggesting no blunting of response in a population heavily weighted toward perimenopausal and postmenopausal women given the mean age. At the 2.4 mg dose at 68 weeks, mean weight loss was 14.9% vs 2.4% placebo in the overall population.

The clinical takeaway across STEP and SURMOUNT: menopause status does not meaningfully attenuate GLP-1 weight-loss response. A post-menopausal woman starting Wegovy or Zepbound should expect response rates broadly similar to what the trial data show in the overall female population.

Should I start HRT or GLP-1 first?

This is a clinical decision that belongs between the patient and her prescriber, but the evidence supports the following framework:

The 2022 NAMS guidance framework (PMID 35797481)

The 2022 NAMS Hormone Therapy Position Statement provides the current clinical standard for HRT initiation:

“For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of [vasomotor symptoms]. Hormone therapy remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture.”

The NAMS statement establishes HRT indication aroundsymptoms (hot flashes, night sweats, vaginal symptoms) and bone protection — not around weight. GLP-1 indication is around obesity (BMI ≥30 for Wegovy/ Zepbound, or BMI ≥27 with weight-related comorbidity). These are parallel tracks, not competing ones.

The practical sequencing guidance most prescribers apply:

• If you have significant vasomotor symptoms or bone density concerns — start HRT first or concurrently. Uncontrolled hot flashes and night sweats will disrupt sleep, increase cortisol, and undermine the lifestyle adherence that GLP-1 therapy works best with. Use a transdermal HRT formulation (patch, gel) to sidestep the tirzepatide oral-absorption interaction.
• If your primary concern is obesity and metabolic risk — GLP-1 therapy can start without waiting for HRT. The two are not pharmacologically incompatible, and GLP-1-driven weight loss may itself improve some menopausal symptoms through reducing adipose-derived estrone conversion and improving cardiometabolic markers.
• If both are indicated — the evidence supports concurrent use. Younglove 2026 (PMID 41883510) documents “potential synergistic effects when MHT is combined with obesity medications,” pending validation by prospective trials. The theoretical basis is sound: HRT corrects the upstream hormonal deficit; GLP-1 addresses the downstream adiposity.

Vaginal estrogen — minimal systemic absorption, no relevant GLP-1 interaction

A specific question that frequently arises: “I'm on Vagifem / Estrace cream / Premarin cream — does this interact with my GLP-1?” The answer is no for any clinically relevant interaction.

The Vagifem prescribing information (DailyMed SetID e5ad3cf6-dd96-4e64-af21-c1eee38d0b88) is a 10 mcg estradiol vaginal insert. The prescribing information documents that systemic absorption of estradiol from vaginal inserts is minimal at the 10 mcg dose — plasma estradiol levels after vaginal insert administration in postmenopausal women are measured at levels consistent with normal postmenopausal baseline or at most slightly above it, not at the elevated levels seen with systemic HRT. This is by design: vaginal estrogen treats genitourinary syndrome of menopause (vaginal dryness, dyspareunia, recurrent UTIs) locally, not systemically.

The pharmacological conclusion: GLP-1-mediated gastric emptying delay has no pathway to affect estradiol delivered directly to vaginal mucosa. There is no oral absorption step. There is no hepatic first-pass metabolism to be affected. Vaginal estrogen at the standard 10 mcg dose also has insufficient systemic levels to interact with any GLP-1 pharmacological mechanism.

Vaginal estrogen + GLP-1: no interaction concern. Patients who ask their prescriber about continuing Vagifem, Estrace cream, or Premarin cream during GLP-1 therapy should receive reassurance that the vaginal route of administration places this product outside the interaction concern category entirely.

The same logic applies to the Estring vaginal ring and Femring vaginal ring: both deliver estradiol locally through vaginal mucosa. Femring does achieve somewhat higher systemic levels than the insert or cream formulations and is considered closer to systemic therapy, but it still bypasses GI absorption entirely and is therefore not affected by GLP-1 gastric emptying.

Tirzepatide + oral hormonal medications: the FDA-label interaction in depth

Because tirzepatide (Zepbound, Mounjaro) is the GLP-1 class member with a specific labeled oral hormonal medication interaction, this warrants detailed clinical consideration for menopausal women on oral HRT formulations.

The clinical pharmacology study that generated the FDA label language tested a single tirzepatide 5 mg dose co-administered with an oral contraceptive containing ethinyl estradiol and norgestimate. The results were significant enough to generate a mandatory label warning:

• Peak concentration reductions of 55–66% for both hormonal components
• Overall AUC reductions of 20–23%
• Absorption timing delayed by 2.5–4.5 hours

These effects are mediated by tirzepatide's gastric emptying delay, which is more pronounced than what semaglutide or liraglutide produce at their therapeutic doses. The effect is also dose-dependent: the study was conducted at 5 mg, the lowest therapeutic tirzepatide dose. The gastric emptying delay is greatest with initial doses and each dose escalation, which is why the label specifically triggers the oral contraceptive warning at “initiation” and “each dose escalation.”

For oral HRT products (estradiol tablets, Premarin tablets, Prometrium progesterone capsules), the same interaction mechanism applies. The clinical consequence is different from contraception — a 20% AUC reduction in oral estradiol might manifest as worsening hot flashes, breakthrough vaginal symptoms, or reduced bone protection efficacy, rather than an unwanted pregnancy. But the pharmacokinetic mechanism is identical.

Practical guidance for women on oral HRT starting tirzepatide:

1. Discuss with your prescriber whether switching to a transdermal formulation (Climara patch, SetID 1e9702c4-f2d7-4ea8-b6e8-7dca31671864; or a gel or spray formulation) makes sense for your clinical situation. Transdermal HRT bypasses the interaction entirely.
2. If remaining on oral HRT, be alert to changes in vasomotor symptom control (more hot flashes, worsening night sweats) that might indicate reduced estrogen absorption — particularly in the first 4 weeks after initiating tirzepatide and the 4 weeks after each dose escalation.
3. Oral progesterone (Prometrium) taken at bedtime may be less affected if taken several hours after the evening meal and well separated from tirzepatide injection days. Discuss timing with your prescriber.
4. The label specifically states that non-oral hormonal medications “should not be affected.” This is the key reassurance: route change resolves the interaction.

Bone density: HRT and GLP-1 considerations

Bone health at menopause is a primary clinical concern: estrogen withdrawal accelerates bone loss, and the WHI (Rossouw 2002, PMID 12117397) documented that HRT reduced hip fracture risk by 34% (HR 0.66, 95% CI 0.45–0.98). GLP-1 therapy introduces a different bone consideration that is relevant when the two are combined.

HRT's role in bone protection: the WHI evidence

The WHI enrolled 16,608 healthy postmenopausal women randomized to conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg or placebo, mean follow-up 5.2 years. Beyond the cardiovascular and cancer outcomes that stopped the trial early, the bone data remain unambiguous: HRT meaningfully reduces fracture risk. The NAMS 2022 position statement (PMID 35797481) confirms prevention of bone loss and fracture as a primary indication for HRT.

GLP-1 and bone: what the evidence shows

Large-magnitude weight loss from any intervention — bariatric surgery, caloric restriction, or pharmacotherapy — can be associated with some reduction in bone mineral density, primarily through two mechanisms: reduced mechanical loading from lower body weight, and reductions in adipose- derived estrogen (estrone) in postmenopausal women. GLP-1s are not unique here: the effect is shared by all weight-loss interventions producing >10% body weight reduction.

The current evidence in GLP-1 specifically does not establish a clinically significant fracture risk increase from semaglutide or tirzepatide at the doses used in STEP and SURMOUNT trials. Bone mineral density was not a primary or registered secondary outcome in either trial, and the 68-week trial duration is insufficient for fracture endpoint analysis. The FDA labels for Wegovy and Zepbound do not include fracture risk as a labeled warning at this time.

The combined HRT + GLP-1 picture on bone: HRT's documented bone-protective mechanism (estrogen maintaining osteoclast-osteoblast balance) is not pharmacologically antagonized by GLP-1. In fact, GLP-1 receptors have been identified on osteoblasts in preclinical models, with potential anabolic bone effects — though this has not translated to a confirmed clinical benefit at the doses used in obesity treatment. For postmenopausal women with osteopenia or osteoporosis risk, continuing HRT (or starting a bone-specific agent like a bisphosphonate) during GLP-1 therapy is a clinically reasonable protective strategy. Discuss DEXA scan timing and monitoring frequency with your prescriber.

Hot flashes and GI side effects: separating overlapping symptoms

A practical clinical challenge: GLP-1 side effects and menopausal symptoms share overlapping features that can confuse both patients and prescribers about which condition is driving which symptom.

The most clinically important scenario: a woman on tirzepatide who develops worsening hot flashes. This could be either (1) menopausal vasomotor symptoms that are being exacerbated by poor HRT absorption due to the oral-medication interaction, or (2) dehydration from GLP-1-induced GI side effects triggering vasodilation. The clinical workup differs for these two etiologies. Discuss with your prescriber before changing either medication.

Compounded BHRT vs FDA-approved HRT: what you need to know

A segment of perimenopausal women are prescribed compounded bioidentical hormone replacement therapy (BHRT) through compounding pharmacies rather than FDA-approved products. This distinction matters for the GLP-1 interaction question.

FDA-approved HRT products (Premarin, Climara, Vagifem, Prometrium, Estrace, and dozens of others) have published prescribing information with pharmacokinetic data, drug interaction studies (however limited), and FDA-reviewed safety profiles. Compounded BHRT products — custom formulations of estradiol, estriol, progesterone, DHEA, or testosterone in individualized doses from a compounding pharmacy — do not have prescribing information, FDA-reviewed pharmacokinetic data, or published drug interaction studies.

The FDA's position on compounded BHRT: the agency does not approve or review compounded hormonal formulations for safety and efficacy. The NAMS 2022 position statement (PMID 35797481) notes concerns about compounded formulations lacking the standardization and pharmacokinetic data of approved products.

For the GLP-1 interaction question specifically: if you are on a compounded oral BHRT formulation, the same gastric-emptying interaction concern that applies to oral FDA-approved HRT would apply — but the pharmacokinetic baseline is less well-characterized, making it harder to judge whether absorption is adequate. If you are on a compounded transdermal or vaginal BHRT formulation, the interaction concern is the same as for FDA-approved transdermal/vaginal products: essentially none.

For verifying whether a compounding pharmacy dispensing your BHRT is operating under appropriate standards, see our pharmacy legitimacy lookup tool.

What to tell your prescriber

If you are on or considering HRT and starting a GLP-1, bring the following specific information to your appointment:

1. Name and formulation of your HRT: Oral tablet, transdermal patch, transdermal gel, vaginal insert, vaginal cream, or vaginal ring. The route determines whether the GLP-1 interaction concern applies.
2. Which GLP-1 you are starting: Tirzepatide (Zepbound/Mounjaro) carries the labeled oral hormonal medication interaction and should trigger a specific discussion about transdermal conversion. Semaglutide (Wegovy/Ozempic) and liraglutide (Saxenda) carry a general gastric-emptying caution but have pharmacokinetic data showing no clinically relevant oral contraceptive interaction.
3. Your current menopause symptom burden: If hot flashes, night sweats, or sleep disruption are significant, HRT adequacy needs to be monitored after GLP-1 initiation and each dose escalation (especially for tirzepatide).
4. Your bone density status: If you have known osteopenia or osteoporosis, discuss whether your HRT dose and bone-monitoring schedule should be adjusted during active weight-loss GLP-1 therapy.
5. Any compounded BHRT: Tell your prescriber the specific formulation, dose, and route so they can evaluate interaction risk appropriately. Bring the prescription label from your compounding pharmacy.
6. Thyroid medication if applicable: Both Wegovy prescribing information and the Rybelsus label note a 33% increase in levothyroxine exposure when taken with oral semaglutide. If you are also on levothyroxine (Synthroid), request a TSH check at your first GLP-1 follow-up visit (see our GLP-1 + levothyroxine interaction guide).

Related research

• GLP-1 and PCOS: the complete evidence review — the women's-health vertical article covering the mechanistic and trial evidence for GLP-1s in polycystic ovary syndrome
• GLP-1 pregnancy, PCOS, fertility & women's health — contraindications in pregnancy, pre-conception discontinuation windows, and fertility-related evidence
• HRT, perimenopause, and GLP-1s: weight management after 40 — companion overview article with WHI primary data, Cochrane body weight review, and Foundayo oral contraceptive interaction
• Birth control and weight loss: what the evidence actually shows — relevant for perimenopausal women deciding between hormonal contraceptive and HRT formulations
• Mounjaro & Zepbound birth control warning: the evidence — deeper detail on the tirzepatide OC interaction including the FDA label language in full
• Spironolactone + GLP-1: potassium, PCOS, and combined use evidence — for women with PCOS who are on spironolactone (Aldactone) for hirsutism or acne alongside a GLP-1; covers the dehydration → GFR → hyperkalemia mechanism, the FDA label drug-interaction data, and the complementary roles of the two drugs in the PCOS women's-health vertical
• GLP-1 side effect questions answered — Q&A hub covering the full side-effect profile
• Complete GLP-1 medication list & reference — full formulary reference covering every approved and investigational GLP-1 medication